Cashu
Vir Biotechnology to Announce Q4 Results and Corporate Update on February 26, 2025
about 1 year ago
Stocks
Health Care
vir
Vir Biotechnology
NASDAQ: VIR
+2.05 (+27.59%)
9.48
USD
At close at Feb 24, 21:43 UTC
Overview
Loading chart...
Key Stats
Market Cap
1.32B
Dividend Yield
0.00%
P/E Ratio
-3.01
EPS
-3.82
Revenue
74.20M
Avg. Volume
3.67M
About
What does VIR do?
Vir Biotechnology is a San Francisco-based clinical-stage immunology company focusing on treatments for infectious diseases, with a pipeline targeting HDV, HBV, HIV, and other viruses. The company went public on October 11, 2019, and employs 587 full-time staff.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.